Total consumer industry cross border M&A deals worth $451.65m were announced in Europe in December 2020, led by Thrasio’s $269.69m acquisition of Maximo Fitness, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 90.8% over the previous month of $4.92bn and a drop of 86.9% when compared with the last 12-month average of $3.45bn.
Europe held a 36.42% share of the global consumer industry cross border M&A deal value that totalled $1.24bn in December 2020. With a 25.09% share and deals worth $311.13m, the UK was the top country in Europe’s cross border M&A deal value across consumer industry.
In terms of cross border M&A deal activity, Europe recorded 21 deals during December 2020, marking an increase of 23.53% over the previous month and a drop of 4.55% over the 12-month average. The UK recorded five deals during the month.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEurope consumer industry cross border M&A deals in December 2020: Top deals
The top five consumer industry cross border M&A deals accounted for 99.9% of the overall value during December 2020.
The combined value of the top five consumer cross border deals stood at $451.16m, against the overall value of $451.65m recorded for the month.
The top five consumer industry cross border M&A deals of December 2020 tracked by GlobalData were:
1) Thrasio’s $269.69m acquisition of Maximo Fitness
2) The $86.5m acquisition of Passoa by Lucas Bols
3) Pollard Banknote’s $44.22m acquisition of Next Generation Lotteries
4) The $41.44m asset transaction with Sportech by BetMakers
5) Vision Healthcare’s acquisition of NaturaMed Pharma for $9.32m.
